Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.

Purpose Of Review: Hematopoietic cell transplantation (HCT) offers potentially curative therapy for patients with myelofibrosis. What is the current status?

Recent Findings: Changes in transplant strategies allow offering HCT to patients who, because of age or comorbid conditions, were not considered transplant candidates in the past. The omission of high-dose total body irradiation, adjusting doses of busulfan to achieve defined target levels, using fludarabine instead of cyclophosphamide as an immunosuppressive agent, the addition of melphalan, and the incorporation of antithymocyte globulin all appear to have contributed to better tolerability of new regimens.